Biologic effects of recombinant hirudin (CGP 39393) in human volunteers

This publication has 12 references indexed in Scilit:

• Recombinant hirudin reduces the incidence of thrombotic occlusion in a canine model of coronary vascular injury
  Coronary Artery Disease, 1991
• Recombinant Hirudin: Genetic Engineering and Structure Analysis
  Seminars in Thrombosis and Hemostasis, 1991
• Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model
  The Annals of Thoracic Surgery, 1991
• Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis.
  Circulation, 1990
• Biology of Recombinant Hirudin (CGP 39393): A New Prospect in the Treatment of Thrombosis
  Seminars in Thrombosis and Hemostasis, 1989
• Development of Hirudin as an Antithrombotic Agent
  Seminars in Thrombosis and Hemostasis, 1989
• Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.
  Journal of Clinical Investigation, 1989
• Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor.
  Circulation, 1989
• FIBRIN, RED CELL AND PLATELET INTERACTIONS IN AN EXPERIMENTAL MODEL OF THROMBOSIS
  British Journal of Pharmacology, 1982
• A pharmacokinetic analysis program (multi) for microcomputer.
  Journal of Pharmacobio-Dynamics, 1981